Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

G.WILLI-FOOD INTERNATIONAL (WILC)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 3
  • 1 comments

Report of Periodic or Interim Report

Market reaction Comment Full text

G.WILLI-FOOD INTERNATIONAL (WILC)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 3
  • 1 comments

Report of Periodic or Interim Report

Market reaction Comment Full text

T1 ENERGY INC. (TE)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 3
  • 1 comments

Technip Energies convoque son assemblée générale annuelle 2026

Market reaction Comment Full text

BANCO SANTANDER S.A. (SAN)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 1
  • 1 comments

Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »

Market reaction Comment Full text

BANCO SANTANDER S.A. (SAN)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 1
  • 1 comments

Press release: Availability of the Q1 2026 aide-mémoire

Market reaction Comment Full text

T1 ENERGY INC. (TE)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 3
  • 1 comments

Technip Energies convenes its 2026 Annual General Meeting

Market reaction Comment Full text

VISTANCE NETWORKS, INC. (VISN)

  • Business News
  • March 24, 2026, 06:30 UTC
  • 3
  • 1 comments

Aurora Networks and HUBER+SUHNER Join Forces to Help Vodafone Germany Develop a Next-Generation Network

Market reaction Comment Full text

BIG SHOPPING CENTERS LTD (BIG)

  • Business News
  • March 24, 2026, 06:23 UTC
  • 1
  • 1 comments

Register of shareholders, changes and capital position

Market reaction Comment Full text

ENERGIX-RENEWABLE ENERGIES LTD (ENRG)

  • Business News
  • March 24, 2026, 06:00 UTC
  • 1
  • 1 comments

Register of shareholders, changes and capital status – exercise of warrants

Market reaction Comment Full text

BANCO SANTANDER S.A. (SAN)

  • Business News
  • March 24, 2026, 06:00 UTC
  • 1
  • 1 comments

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Market reaction Comment Full text
  • Previous
  • 347
  • 348
  • 349
  • 350
  • 351
  • Next

Search

News categories

  • Technical Exchange News(11551)
  • Event(3509)
  • SEC News(218335)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(138310)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin